Ehlers-Danlos Syndrome (EDS) is a group of connective tissue disorders with no autoimmune characteristics. Connective tissue (such as tendons, ligaments, fat, bone, cartilage) plays a pivotal role in maintaining the structural and functional integrity of the human body. It serves not only as the supportive framework for organs and tissues but also mediates force transmission and tissue elasticity, which are essential for movement and body coordination. Connective tissue protects and insulates vital organs and is composed primarily of collagen, elastin and other extracellular matrix components, which facilitate cellular signaling and tissue repair processes.
EDS and Collagen
EDS results from genetic mutations that affect collagen production and its effectiveness in connective tissue. EDS in the skin and joints is characterized by:
- Hypermobility — An unusually high range of movement in joints
- Hyperextensibility — Characterized by an abnormal increase in the flexibility of the skin and other connective tissues.
- Tissue fragility — Fragility of the skin, tendons and internal organs
Vascular EDS
Vascular EDS, one of the most severe forms of the disorder, results in compromised type III collagen that weakens the blood vessels and hollow organs. It is rare and potentially fatal. Vascular EDS patients are prone to dangerous complications such as arterial rupture, organ perforation and other life-threatening events, often occurring at a relatively young age. Early detection and monitoring of potential vascular issues are critical, requiring regular imaging and cardiovascular evaluations. Our treatment team has experience and extensive knowledge in treating vascular EDS.
Causes and Genetics of Ehlers-Danlos Syndrome
EDS results from genetic mutations in the genes responsible for collagen production and processing. EDS is broadly classified into thirteen subtypes, each defined by a unique set of clinical criteria and genetic etiology.
Mutations in the COL5A1 and COL5A2 lead to the characteristic skin and joint changes. The vascular type of EDS is linked to mutations in the COL3A1 or COL1A1 genes, where type III collagen is compromised, resulting in more severe manifestations and an increased risk of vascular complications.
Most of the genetic mutations for EDS are autosomal dominant — where a single copy of the mutated gene, inherited from either parent, is sufficient to cause the disorder. With this inheritance pattern, patients have a 50% chance of passing the mutation to their children. Genetic counseling is important so that affected individuals and their families understand the implications for future generations.
Symptoms of Ehlers-Danlos Syndrome
It is possible to live with EDS and not know you have it. EDS patients often exhibit a distinct array of common physical manifestations that can significantly affect their daily lives.
Hypermobility
This is an unusually high range of movement in joints. It predisposes individuals to frequent joint dislocations and sprains, which can significantly impair daily activities and increase the risk of long-term joint deterioration. Hypermobility is not solely associated with skeletal joints. It can affect various bodily systems, potentially compromising cardiovascular function and contributing to complications such as autonomic dysfunction.
Hyperextensibility
Hyperextensibility is characterized by an abnormal increase in the flexibility of the skin and other connective tissues. It typically manifests as skin that stretches with ease but can also result in various functional challenges and makes it more prone to injuries and complications such as excessive bruising, scarring and the development of redundant skin folds. Tendons and ligaments may also exhibit hyperextensibility, leading to joint instability, frequent dislocations and compromised joint function.
Tissue Fragility
Collagen plays a central role in the structural integrity of various bodily tissues. Defects in collagen production or function leads to fragility of the skin, tendons and internal organs. Patients are prone to bruising, scarring and the development of various dermal and subdermal complications. The fragility can also result in internal issues such as hernias or early-onset osteoarthritis. Patients may experience significant challenges in wound healing, as the delicate structure of connective tissues often impedes normal regenerative processes.
Blood Vessel and Organ Rupture
People with vascular EDS often have thin, translucent skin that is prone to bruising and easily visible veins. Collagen provides strength and structure so that blood vessels can withstand injury and pressure. Weakened collagen makes patients prone to spontaneous arterial ruptures and aneurysms. This weakness can extend to the patient's organs, with the intestines and uterus being some of the more commonly affected sites. Patients also frequently report chronic pain and early-onset varicose veins.
Chronic Pain
EDS pain is often chronic and can vary greatly in intensity. It is usually constant and severe. It can be musculoskeletal due to joint instability and frequent dislocations, or neuropathic pain from the compression of nerves by unstable or excessively mobile joints. Headaches are a common complaint, potentially due to cervical spine instability or vascular issues.
Gastrointestinal (Digestive) Complications
EDS patients often experience gastrointestinal complications, including delayed gastric emptying or reflux. Delayed gastric emptying (gastroparesis) occurs when stomach muscles do not function properly, leading to incomplete digestion and symptoms such as bloating, nausea and vomiting. As a result, individuals may face nutritional challenges and require dietary modifications to manage their symptoms effectively. In certain types of EDS, spontaneous intestinal perforation can occur.
Reflux, or gastroesophageal reflux disease (GERD), is also prevalent in EDS patients, as compromised connective tissue can affect the esophageal sphincter, allowing acid to escape from the stomach into the esophagus. This condition can lead to heartburn, regurgitation and potential esophageal damage if not adequately controlled.
Diagnosing EDS
We start with a detailed medical history and thorough physical examination, with a focus on typical EDS symptoms such as joint hypermobility, skin hyperextensibility and the fragility of connective tissues.
Genetic testing plays a crucial role in the EDS diagnostic process, offering significant insights into the specific genetic mutations that underlie the condition. Through the utilization of advanced techniques such as next-generation sequencing (NGS), individuals suspected of having EDS can be thoroughly screened for known mutations across the multiple genes associated with the disorder. This comprehensive approach not only accurately classifies EDS subtypes, but also aids in differentiating EDS from other connective tissue disorders with overlapping symptoms. Genetic testing provides valuable information for genetic counseling, enabling families to understand the inheritance patterns and potential implications for future generations.
EDS is rare, so many health care professionals may be unfamiliar with the nuances of diagnosing EDS, potentially impacting the timeliness and accuracy of diagnosis. It's important that the clinical assessment includes specialists across various disciplines — including dermatologists, geneticists, rheumatologists, cardiologists, orthopaedic specialists and vascular surgeons.
Treatment for Ehlers-Danlos Syndromes
There is no cure for EDS, so we look to treat the symptoms of EDS. EDS management strategies focus on symptom relief and maintaining quality of life, tailored to the individual's specific subtype and symptoms. These strategies involve a combination of physical therapy and occupational therapy to improve joint stability and function, while also recommending protective measures to prevent injury. Ask your care team about alternative methods, such as acupuncture or cognitive behavioral therapy.
Medications and lifestyle adjustments play a vital role in EDS management, providing symptom relief and enhancing quality of life. Medications focus on managing pain and mitigating symptoms that stem from joint instability and tissue fragility. Some patients benefit from medications that target specific symptoms, such as antihistamines for those experiencing allergic reactions due to mast cell activation, which can be prevalent in some EDS subtypes.
Lifestyle adjustments can minimize symptoms and promote overall wellbeing. Individuals with EDS are encouraged to adopt low-impact exercise routines, such as swimming or Pilates, that enhance muscle function and joint stability without overloading the connective tissues. It's best to avoid high-impact sports, such as football or basketball.
Prognosis and Living With EDS
Life expectancy for EDS patients can vary considerably based on the specific subtype. Certain complications, such as vascular issues, are more common in the vascular subtype and may pose a significant risk. For most individuals, life expectancy is relatively normal, though the chronic symptoms and complex nature of EDS may affect quality of life.
Managing symptoms can require daily treatment and self-care regimens. Joint instability and chronic pain can disrupt normal activities and can lead to emotional and psychological stress. It's important to adopt a multidisciplinary approach, including specialists who deal with genetic disorders, physical therapy to maintain mobility and psychological support to foster mental resilience.
Community and support networks play a vital role in the lives of EDS patients, providing much-needed emotional and practical assistance. For many patients and families, connecting with others who understand the unique challenges of EDS provides a sense of community and belonging, reducing feelings of isolation often associated with rare disorders. These networks facilitate the exchange of practical advice on navigating health care, accessing specialized medical care and implementing effective day-to-day management strategies. For more information, visit ehlers-danlos.com.
Future Directions in Research and Treatment
Future EDS research and treatment approaches focus on the development and integration of new genetic insights and innovative therapy. With advancements in genetic sequencing technologies, researchers are better equipped to explore EDS genetics, potentially identifying new mutations that could refine subtype classifications. Such discoveries may pave the way for gene-targeted therapies, enabling precision medicine approaches that tailor interventions specifically to an individual's genetic makeup.
There is increasing attention on the molecular mechanisms and biological pathways affected by EDS-related mutations. This could reveal actionable drug targets and biomarkers for disease progression.
